title: Real-world outcome from ST elevation myocardial infarction in the very elderly before and after the introduction of a 24/7 primary percutaneous coronary intervention service.
abstract: BACKGROUND
  It remains unclear whether the superiority of primary percutaneous coronary intervention (PPCI) over thrombolysis for the treatment of ST elevation myocardial infarction (STEMI) extends to the very elderly. Furthermore, the deliverability and efficacy of PPCI in over the 80s has not been investigated in a real-world setting. The aim of this study was to compare outcome from STEMI in patients aged > or =80 before and after the introduction of routine 24/7 PPCI.
  
  
  METHODS
  Retrospective observational analysis of all patients aged > or =80 presenting with STEMI to 2 neighboring hospitals in the 3-year period after the introduction of a 24/7 PPCI service and in the preceding 2 years when reperfusion therapy was by thrombolysis.
  
  
  RESULTS
  Two hundred fifty-six STEMI patients aged > or =80 were included. After the introduction of PPCI, 84% (136/161) received reperfusion therapy, 73% PPCI, and 12% thrombolysis, compared to 77% ([73/95] 1% PPCI, 76% thrombolysis) previously. Mortality after inception of PPCI was reduced at 12 months (29% vs 41%, P = .04) and 3 years (43% vs 58%, P = .02). Improved outcome was attributable to treatment by PPCI, which was associated with numerically lower 12-month (26% vs 37%, P = .07) and significantly reduced 3-year (42% vs 55%, P = .05) mortality compared to thrombolysis.
  
  
  CONCLUSIONS
  Primary PCI can be effectively delivered to very elderly patients presenting with ST elevation MI in a real-world setting and leads to a substantial reduction in mortality compared to patients treated by thrombolysis.
authors.affiliation: Leeds General Infirmary, Leeds, United Kingdom.
authors.forename: Rhidian J
authors.initials: RJ
authors.lastname: Shelton
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Crean
authors.forename: Kathryn
authors.initials: K
authors.lastname: Somers
authors.forename: Claire
authors.initials: C
authors.lastname: Priestley
authors.forename: Carol
authors.initials: C
authors.lastname: Hague
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Blaxill
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Wheatcroft
authors.forename: James M
authors.initials: JM
authors.lastname: McLenachan
authors.forename: John P
authors.initials: JP
authors.lastname: Greenwood
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Blackman
mesh_terms: D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D017023:Coronary Angiography; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D012189:Retrospective Studies; D015912:Thrombolytic Therapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents